UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015208
Receipt number R000017563
Scientific Title Double-blind, placebo-controlled study to evaluate adjuvanticity effects of Pleurotus cornucopiae extracts.
Date of disclosure of the study information 2014/09/19
Last modified on 2015/04/28 10:17:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Double-blind, placebo-controlled study to evaluate adjuvanticity effects of Pleurotus cornucopiae extracts.

Acronym

Adjuvanticity effects of Pleurotus cornucopiae extracts.

Scientific Title

Double-blind, placebo-controlled study to evaluate adjuvanticity effects of Pleurotus cornucopiae extracts.

Scientific Title:Acronym

Adjuvanticity effects of Pleurotus cornucopiae extracts.

Region

Japan


Condition

Condition

immunodepletion

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the adjuvanticity of Pleurotus cornucopiae extract, 80mL daily ingestion for 8 weeks, and to prove its beneficial effects. Additionally to evaluate anti-stress, blood pressure lowering, blood sugar improving effects and to evaluate the overall health promotion and maintenance by Pleurotus cornucopiae extracts.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase III


Assessment

Primary outcomes

Natural killer cell activity

Key secondary outcomes

Blood cortisol, IL-12, MIF, serum neopterin, blood pressure, fasting blood glucose, HbA1c, VAS questionnaire


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Pleurotus cornucopiae extracts 80mL per day for 8 weeks

Interventions/Control_2

Placebo 80 mL per day for 8 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1. Subjects who show low NK cell activity.
2. Subjects who agree to participate in the current study with written informed consent.

Key exclusion criteria

1. Subjects who are under medication for chronic ailments (especially diseases related to cancer, liver, kidney, heart, gastrointestinal tract, diabetes, hypertension, mental disorder etc)
2. Subjects with serious diseases or infections such as cerebrovascular, cardiac, liver, kidney, gastrointestinal tract or condition which need immediate reporting to the authorities
3. Subjects who are suspected of acute infection morbidity from diseases such as influenza
4. Subjects who undergo treatment for chronic inflammatory diseases autoimmune diseases or allergies etc
5. Subjects who receive vaccination 12 weeks before participating in this study or those who will get inoculated during this study period
6. Subjects who have a major surgical history such as gastrectomy, gastrointestinal suture surgery or intestinal resection etc
7. Subjects with frequent complaints of post-menopausal symptoms
8. Subjects with unusually high and/or low blood pressure, or with abnormal hematological data
9. Subjects with serious anemia
10. Subjects with a history of allergy to medicine and food (especially mushroom, soybean, wheat)
11. Subjects who regularly undertake medication which can affect the immune function (antibiotics, immunosuppressive drugs, anti-inflammatory drugs, anti-rheumatic drugs, antihistamines, anti-allergy drugs, lactic acid bacteria supplements etc.) Chinese herbal medicine, health food, supplements, extracts from (mushroom, seaweed, nucleic acids, yeast, lactic acid bacteria etc)
12. Heavy smokers, alcohol addicts or subjects with irregular lifestyle
13. Subjects who donate either 400ml whole blood within 12 weeks or plasma, platelets within 4 weeks or blood component within 2 weeks prior to this study
14. Subjects who are pregnant or under lactation or ones who would expect to be pregnant during the study
15. Subjects who participate in other clinical trials within the last one month prior to the current clinical trial
16. Subjects who are ineligible due to physician's judgment

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Prof. Jun Nishihira, M.D.

Organization

Hokkaido Information University

Division name

Department of Medical Management and Informatics

Zip code


Address

59-2, Nishi Nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4411

Email

nishihira@do-johodai.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Dir. Prof. Jun Nishihira, M.D.

Organization

Hokkaido Information University

Division name

Health Information Science Center

Zip code


Address

59-2, Nishi Nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4430

Homepage URL


Email

nishihira@do-johodai.ac.jp


Sponsor or person

Institute

Hokkaido Information University

Institute

Department

Personal name



Funding Source

Organization

Three B Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道情報大学 保健センター(北海道)


Other administrative information

Date of disclosure of the study information

2014 Year 09 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 07 Month 30 Day

Date of IRB


Anticipated trial start date

2014 Year 09 Month 09 Day

Last follow-up date

2014 Year 12 Month 03 Day

Date of closure to data entry

2014 Year 12 Month 10 Day

Date trial data considered complete

2014 Year 12 Month 19 Day

Date analysis concluded

2015 Year 01 Month 27 Day


Other

Other related information



Management information

Registered date

2014 Year 09 Month 19 Day

Last modified on

2015 Year 04 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017563


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name